Bacterial Conjunctivitis

Pipeline Programs

Companies

Clinical Trials

Approved Products

Pipeline by Development Stage

Preclinical

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

On Market

Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule

5100%

+ 21 programs with unclassified modality

On Market (2)

Approved therapies currently available

BESIVANCEApproved

besifloxacin

Bausch + Lomb

Quinolone Antimicrobial [EPC]ophthalmic2009

11M Part D

ZYMAXIDApproved

gatifloxacin

AbbVie

ophthalmic2010

Competitive Landscape

8 companies ranked by most advanced pipeline stage

Pre

P1/2

P2/3

Mkt

AlconFORT WORTH, TX

7 programs

VIGAMOXPhase 41 trial

Vigamox Ophthalmic SolutionPhase 41 trial

Moxifloxacin Alternative FormulationPhase 31 trial

Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%Phase 31 trial

Moxifloxacin ophthalmic solution, 0.5%Phase 31 trial

+2 more programs

Active Trials

NCT01238783Withdrawn0

NCT00759148Completed1,179Est. Mar 2010

NCT00332293Completed695Est. Dec 2006

+4 more trials

Bausch + LombNJ - Bridgewater

5 programs

BesifloxacinPhase 3Small Molecule

BesivancePhase 3

BesifloxacinPhase 2/3Small Molecule

ISV-403Phase 2

AbbVieNORTH CHICAGO, IL

3 programs

gatifloxacinPhase 4Small Molecule1 trial

Gatifloxacin 0.5% eye dropsPhase 31 trial

Active Trials

NCT00518089Completed859Est. Jan 2009

NCT00509873Completed578Est. Jun 2008

NCT00464438Completed171Est. Sep 2008

Bausch HealthQUEBEC, Quebec, Canada

5 programs

BesifloxacinPhase 3Small Molecule1 trial

BesivancePhase 31 trial

BesifloxacinPhase 2/3Small Molecule1 trial

ISV-403Phase 21 trial

Active Trials

NCT00622908Completed270Est. Jun 2005

NCT00972777Completed474Est. Feb 2011

NCT01740388Terminated136Est. Nov 2013

+2 more trials

Sharp TherapeuticsPA - Pittsburgh

2 programs

AzaSitePhase 3

MSDIreland - Ballydine

2 programs

AzaSitePhase 31 trial

Active Trials

NCT00105469Completed743Est. Oct 2005

NCT00105534Completed685Est. Jan 2006

BiocorpFrance - Issoire

1 program

azithromycin eye drops by essexPhase 1

Essex BioChina - Hong Kong

1 program

azithromycin eye drops by essexPhase 11 trial

Active Trials

NCT03235141Unknown56Est. Dec 2017

Trial Timeline

Clinical trial activity over time

2021

2022

2023

2024

2025

2026

AlconVigamox Ophthalmic Solution

AbbViegatifloxacin

AlconVIGAMOX

Bausch HealthBesifloxacin

AlconMoxifloxacin ophthalmic solution, 0.5%

Bausch HealthBesivance

AlconMoxifloxacin Alternative Formulation

AbbVieGatifloxacin 0.5% eye drops

AlconMoxifloxacin Alternative Formulation Ophthalmic Solution 0.5%

Alconquinolone

MSDAzaSite

Bausch HealthBesifloxacin

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 8,143 patients across 18 trials

NCT00798577 AlconVigamox Ophthalmic Solution

Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment

Start: Oct 2008Est. completion: Feb 200924 patients

Phase 4Completed

NCT00464438 AbbViegatifloxacin

A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis

Start: Jun 2007Est. completion: Sep 2008171 patients

Phase 4Completed

NCT00312338 AlconVIGAMOX

Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora

Start: Jun 2006Est. completion: Jun 2007137 patients

Phase 4Completed

NCT01740388 Bausch HealthBesifloxacin

Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis

Start: Feb 2013Est. completion: Nov 2013136 patients

Phase 3Terminated

NCT01573910 AlconMoxifloxacin ophthalmic solution, 0.5%

An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients

Start: May 2012Est. completion: Apr 2014985 patients

Phase 3Completed

NCT01330355 Bausch HealthBesivance

Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis

Start: May 2011Est. completion: Oct 201333 patients

Phase 3Terminated

NCT01175590 Bausch HealthBesivance

Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

Start: Jun 2010Est. completion: Feb 2012518 patients

Phase 3Completed

NCT00759148 AlconMoxifloxacin Alternative Formulation

Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis

Start: Oct 2008Est. completion: Mar 20101,179 patients

Phase 3Completed

NCT00518089 AbbVieGatifloxacin 0.5% eye drops

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Start: Feb 2008Est. completion: Jan 2009859 patients

Phase 3Completed

NCT00509873 AbbVieGatifloxacin 0.5% eye drops

A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis

Start: Aug 2007Est. completion: Jun 2008578 patients

Phase 3Completed

NCT00332293 AlconMoxifloxacin Alternative Formulation Ophthalmic Solution 0.5%

AL-15469A for the Treatment of Bacterial Conjunctivitis

Start: May 2006Est. completion: Dec 2006695 patients

Phase 3Completed

NCT00331916 Alconquinolone

AL-15469A for the Treatment of Bacterial Conjunctivitis

Start: Nov 2005600 patients

Phase 3Completed

NCT00105534 MSDAzaSite

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)

Start: Jul 2004Est. completion: Jan 2006685 patients

Phase 3Completed

NCT00105469 MSDAzaSite

Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)

Start: Jul 2004Est. completion: Oct 2005743 patients

Phase 3Completed

NCT00972777 Bausch HealthBesifloxacin

Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis

Start: Oct 2009Est. completion: Feb 2011474 patients

Phase 2/3Completed

NCT01238783 AlconAL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension

Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis

Start: Jan 20110

Phase 2Withdrawn

NCT00622908 Bausch HealthISV-403

Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis

Start: Dec 2004Est. completion: Jun 2005270 patients

Phase 2Completed

NCT03235141 Essex Bioazithromycin eye drops by essex

Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers

Start: Jul 2017Est. completion: Dec 201756 patients

Phase 1Unknown

Phase Legend

Preclinical— Lab & animal studies

Phase 1— Safety & dosing

Phase 2— Efficacy testing

Phase 3— Large-scale trials

On Market— Approved & available

Key Insights

16 late-stage (Phase 3) programs, potential near-term approvals

8 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.